Japanische Biotechnologie in Deutschland

Article Abstract:

In cooperation with a partner, the Japanese Tokyo-based pharmaceutical company Chugai Pharma is to launch a biopharmaceutical product in Germany. A marketing organisation is to be set up in Frankfurt. At present, Chugai is marketing two biopharmaceutical medicines, the granylocyte-colony-stimulating "Neutrogin" (in Europe available as "Granocyte") and the erythropoietin "Epogin" (not available in Europe), which contributed altogether 591mn to the pharmaceutical company's total turnover of 185.6bn in 1997.

Comment:

To launch a biopharmaceutical product in Germany in cooperation with a partner

Product introduction, Chugai Pharmaceutical Company Ltd., Article

---

GERMANY: MEISSNER & WURST WIN INSULIN PLANT JOB

Article Abstract:

Hoechst Marion Roussel (HMR) of Frankfurt and Pfizer Inc. of New York have placed a contract with Stuttgart-based Life Sciences Meissner & Wurst GmbH (LSMW) for the planning of the world's biggest insulin production plant by mid-1999. The plant to be built in Hoechst, Frankfurt, will produce inhalable insulin. The contract that is worth a double-digit million amount includes an option for the construction of the plant. LSMW is a joint venture of German M & W Zander and Day & Zimmermann of the US.

Heavy construction, not elsewhere classified, All Other Heavy Construction, New orders received, Heavy Construction NEC, Engineering Services, Drugs, Construction industry, Heavy construction, Pfizer Inc., PFE, Hoechst Marion Roussel AG, Life Sciences Meissner and Wurst GmbH

---

AUSTRIA: BIOCHEMIE EXPANDING OVERSEAS

Article Abstract:

Austrian Biochemie of Kundl, a subsidiary of Novartis and a leading producer of antibiotics worldwide, is investigating investment opportunities in Latin America. For 1999 Biochemie is expecting a 5% increase in sales from Sch 9.936bn in 1998, to which exports contributed 96.8%. In future turnover is grow by Sch 1bn annually. Biochemie is spending Sch 100mn on a research facility in India, which is to be completed in two years.

Austria, Foreign operations, Research & development outlays, Pharmaceutical Preparation Manufacturing, Antiinfective Preparations, India, Latin America, Statistical Data Included, Anti-infective agents, Biochemie GmbH

Similar abstracts:

• Abstracts: Druckfarbenproduktion in Deutschland GERMANY: GROWTH EXPECTED IN ADHESIVE MARKET
• Abstracts: GERMANY: LESS CFC-CONTAINING REFRIGERANTS. GERMANY: EPOXY RESINS WITH NEW TECHNOLOGY. Bayer noch st rker mit Polyisocyanaten

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.